pmid	doi	year	title	Hugo_Symbol
32393046	10.1080/09603123.2020.1757043	2022	The expression of microRNAs and exposure to environmental contaminants related to human health: a review.	HLA-A
33648421	10.1080/07391102.2021.1889669	2022	<i>In silico</i> identification of epitope-based vaccine candidates against HTLV-1.	HLA-A
34926267	10.3389/fonc.2021.765544	2022	<i>SEPT6</i>_<i>TRIM33</i> Gene Fusion and Mutated TP53 Pathway Associate With Unfavorable Prognosis in Patients With B-Cell Lymphomas.	HLA-A
35176142	10.1158/2326-6066.CIR-21-0307	2022	A Costimulatory CAR Improves TCR-based Cancer Immunotherapy.	HLA-A
35254876	10.1200/JCO.21.01805	2022	Phase I Study of Safety, Tolerability, and Efficacy of Tebentafusp Using a Step-Up Dosing Regimen and Expansion in Patients With Metastatic Uveal Melanoma.	HLA-A
35358442	10.1016/S2352-3026(22)00036-9	2022	In-vivo T-cell depleted reduced-intensity conditioned allogeneic haematopoietic stem-cell transplantation for patients with acute lymphoblastic leukaemia in first remission: results from the prospective, single-arm evaluation of the UKALL14 trial.	HLA-A
35504960	10.1038/s41598-022-11247-z	2022	A retrospective study on the clinicopathological and molecular features of 22 cases of natural killer/T-cell lymphoma in children and adolescents.	HLA-A
35759244	10.1002/iid3.666	2022	EBV protection- and susceptibility-related HLA alleles and EBV status in the Chinese population: A single-center study.	HLA-A
35840432	10.1016/j.transproceed.2022.05.005	2022	Successful Kidney and Hematopoietic Stem Cell Transplantation for Malignant Lymphoma from Different Donors: A Case Report and Literature Review.	HLA-A
35845006	10.1002/jha2.116	2022	Genetic aberrations of <i>NLRC5</i> are associated with downregulated MHC-I antigen presentation and impaired T-cell immunity in follicular lymphoma.	HLA-A
35953408	10.1016/j.humimm.2022.08.002	2022	HLA homozygosity is associated with Non-Hodgkin lymphoma.	HLA-A
36081501	10.3389/fimmu.2022.993025	2022	Potential role of HTLV-1 Tax-specific cytotoxic t lymphocytes expressing a unique t-cell receptor to promote inflammation of the central nervous system in myelopathy associated with HTLV-1.	HLA-A
28659916	10.3389/fimmu.2017.00675	2021	HLA-Bw4-I-80 Isoform Differentially Influences Clinical Outcome As Compared to HLA-Bw4-T-80 and HLA-A-Bw4 Isoforms in Rituximab or Dinutuximab-Based Cancer Immunotherapy.	HLA-A
28811957	10.1080/2162402X.2017.1321184	2021	Mapping the human T cell repertoire to recurrent driver mutations in MYD88 and EZH2 in lymphoma.	HLA-A
29147614	10.1080/2162402X.2017.1356964	2021	Exploiting a new strategy to induce immunogenic cell death to improve dendritic cell-based vaccines for lymphoma immunotherapy.	HLA-A
32072624	10.1111/bjh.16398	2021	Variation in the Human Leukocyte Antigen system and risk for endemic Burkitt lymphoma in northern Uganda.	HLA-A
32079700	10.3324/haematol.2019.236836	2021	Identification of an immunogenic DKK1 long peptide for immunotherapy of human multiple myeloma.	HLA-A
32311478	10.1016/j.bbmt.2020.04.006	2021	Development of a Unique T Cell Receptor Gene-Transferred Tax-Redirected T Cell Immunotherapy for Adult T Cell Leukemia.	HLA-A
32883310	10.1186/s12977-020-00536-y	2021	HLA-B*35 as a new marker for susceptibility to human T-cell lymphotropic virus type 1 (HTLV-1) Associated Myelopathy/Tropical Spastic Paraparesis (HAM/TSP) in patients living in Argentina.	HLA-A
32964767	10.1080/10428194.2020.1821011	2021	Frequent mutations in HLA and related genes in extranodal NK/T cell lymphomas.	HLA-A
32973816	10.3389/fimmu.2020.02076	2021	Sintilimab-Induced Autoimmune Diabetes in a Patient With the Anti-tumor Effect of Partial Regression.	HLA-A
33267617	10.1177/0963689720976567	2021	Hematopoietic Stem Cell Transplantation From a Related Donor with Human Leukocyte Antigen 1-Antigen Mismatch in the Graft-Versus-Host Direction Using Low-dose Anti-thymocyte Globulin.	HLA-A
33410215	10.1111/cas.14800	2021	Short-term cultured autologous peripheral blood mononuclear cells as a potential immunogen to activate Tax-specific CTL response in adult T-cell leukemia patients.	HLA-A
34128753	10.1080/10428194.2021.1929958	2021	Combined impact of HLA-allele matching and the CD34-positive cell dose on optimal unit selection for single-unit cord blood transplantation in adults.	HLA-A
29204156	10.1155/2017/6527306	2020	Sp17 Protein Expression and Major Histocompatibility Class I and II Epitope Presentation in Diffuse Large B Cell Lymphoma Patients.	HLA-A
30396848	10.1016/j.jcyt.2018.08.001	2020	Epstein-Barr Virus (EBV)-derived BARF1 encodes CD4- and CD8-restricted epitopes as targets for T-cell immunotherapy.	HLA-A
30715139	10.1093/asj/sjz021	2020	Differences in Human Leukocyte Antigen Expression Between Breast Implant-Associated Anaplastic Large Cell Lymphoma Patients and the General Population.	HLA-A
31066027	10.1002/cpt.1493	2020	Shared Genetic Risk Factors Across Carbamazepine-Induced Hypersensitivity Reactions.	HLA-A
31092896	10.1038/s41375-019-0473-1	2020	Molecular heterogeneity in peripheral T-cell lymphoma, not otherwise specified revealed by comprehensive genetic profiling.	HLA-A
31155783	10.1111/joim.12911	2020	The role of HLA variation in lymphoma aetiology and survival.	HLA-A
31215275	10.1080/10428194.2019.1617858	2020	The association between HLA and non-Hodgkin lymphoma subtypes, among a transplant-indicated population.	HLA-A
31883669	10.1016/j.pathol.2019.09.014	2020	The clinicopathological and genetic features of ovarian diffuse large B-cell lymphoma.	HLA-A
31958417	10.1016/S2352-3026(19)30220-0	2020	Addition of anti-thymocyte globulin to standard graft-versus-host disease prophylaxis versus standard treatment alone in patients with haematological malignancies undergoing transplantation from unrelated donors: final analysis of a randomised, open-label, multicentre, phase 3 trial.	HLA-A
32257153	10.7189/jogh.10.010405	2020	Risk factors for Epstein Barr virus-associated cancers: a systematic review, critical appraisal, and mapping of the epidemiological evidence.	HLA-A
32808978	10.1093/infdis/jiaa512	2020	Identification of Functional HLA-A*01 :01-Restricted EBV-LMP2-Specific T-cell Receptors.	HLA-A
29367710	10.1038/s41409-017-0084-2	2019	The Japan Marrow Donor Program, 25 years of experience in achieving 20,000 bone marrow transplantations: organization structure, activity, and financial basis.	HLA-A
29441070	10.3389/fimmu.2018.00099	2019	A Recurrent Mutation in Anaplastic Lymphoma Kinase with Distinct Neoepitope Conformations.	HLA-A
29467338	10.1172/jci.insight.97805	2019	TCR-mimic bispecific antibodies targeting LMP2A show potent activity against EBV malignancies.	HLA-A
29496759	10.1158/1078-0432.CCR-17-2483	2019	The RNA-binding Protein MEX3B Mediates Resistance to Cancer Immunotherapy by Downregulating HLA-A Expression.	HLA-A
29661776	10.1158/1078-0432.CCR-17-2626	2019	Targeting the Leukemia Antigen PR1 with Immunotherapy for the Treatment of Multiple Myeloma.	HLA-A
30123963	10.1111/tan.13379	2019	Identification of the novel HLA-A*29:113 allele in a Hodgkin's Lymphoma patient.	HLA-A
30311452	10.1111/tan.13406	2019	Two novel alleles, HLA-A*32:01:01:09 and 32:01:01:10, identified by Pacific Bioscience's SMRT sequencing.	HLA-A
30864683	10.3892/ijo.2019.4740	2019	TOPK is regulated by PP2A and BCR/ABL in leukemia and enhances cell proliferation.	HLA-A
27090957	10.1016/j.bbmt.2016.04.007	2018	Killer Cell Immunoglobulin-Like Receptor-Ligand Matching and Outcomes after Unrelated Cord Blood Transplantation in Acute Myeloid Leukemia.	HLA-A
27273744	10.1111/tan.12829	2018	The effect of missing KIR ligands, activating KIR genotype and haplotype on the outcome of T-cell-replete hematopoietic stem cell transplantation from HLA-identical siblings in Thai patients.	HLA-A
27776339	10.18632/oncotarget.12778	2018	Generation of CD20-specific TCRs for TCR gene therapy of CD20low B-cell malignancies insusceptible to CD20-targeting antibodies.	HLA-A
28126967	10.3324/haematol.2016.158584	2018	The effect of inter-unit HLA matching in double umbilical cord blood transplantation for acute leukemia.	HLA-A
28677225	10.1111/tan.13081	2018	Identification of a new HLA-A allele, HLA-A*02:07:09, in a Chinese non-Hodgkin lymphoma patient.	HLA-A
28948342	10.1007/s00403-017-1783-7	2018	Pediatric mycosis fungoides: a study of the human leukocyte antigen system among Israeli Jewish patients.	HLA-A
28981945	10.3760/cma.j.issn.1003-9406.2017.05.026	2018	[Association of HLA-A, -B, -DRB1 alleles and haplotypes with acute lymphoblastic leukemia among ethnic Hans from northern China].	HLA-A
29080718	10.1016/j.humimm.2017.10.010	2018	Sex-specific survival difference in association with HLA-DRB1∗04 following allogeneic haematopoietic stem cell transplantation for lymphoid malignancies.	HLA-A
26537309	10.1111/jdv.13462	2017	Carbamazepine-induced HLA-A*3101 associated hypersensitivity syndrome mimicking mycosis fungoides.	HLA-A
26636741	10.1097/TP.0000000000001025	2017	HLA and Risk of Diffuse Large B cell Lymphoma After Solid Organ Transplantation.	HLA-A
27007051	10.18632/oncotarget.8198	2017	Artificial antigen-presenting cells expressing AFP(158-166) peptide and interleukin-15 activate AFP-specific cytotoxic T lymphocytes.	HLA-A
27063556	10.1016/j.gene.2016.04.017	2017	The associations of HLA-A, -B, DRB1 alleles and haplotypes in Turkish lymphoma patients.	HLA-A
27095065	10.4274/tjh.2016.0102	2017	The Frequency of HLA-A, HLA-B, and HLA-DRB1 Alleles in Patients with Acute Lymphoblastic Leukemia in the Turkish Population: A Case-Control Study.	HLA-A
27104753	10.3109/10428194.2016.1173209	2017	Association between HLA-A1 and -A2 types and Epstein-Barr virus status of post-transplant lymphoproliferative disorder.	HLA-A
27414060	10.1111/cei.12842	2017	Analysis of nucleophosmin-anaplastic lymphoma kinase (NPM-ALK)-reactive CD8(+) T cell responses in children with NPM-ALK(+) anaplastic large cell lymphoma.	HLA-A
28252558	10.1097/TP.0000000000001713	2017	Mismatched HLA-DRB3 Can Induce a Potent Immune Response After HLA 10/10 Matched Stem Cell Transplantation.	HLA-A
28334025	10.1371/journal.pone.0174457	2017	HLA expression and HLA type associations in relation to EBV status in Hispanic Hodgkin lymphoma patients.	HLA-A
28627735	10.1111/cas.13303	2017	Genetic alterations in adult T-cell leukemia/lymphoma.	HLA-A
28724766	10.1128/JVI.00974-17	2017	A Unique T-Cell Receptor Amino Acid Sequence Selected by Human T-Cell Lymphotropic Virus Type 1 Tax<sub>301-309</sub>-Specific Cytotoxic T Cells in HLA-A24:02-Positive Asymptomatic Carriers and Adult T-Cell Leukemia/Lymphoma Patients.	HLA-A
25648508	10.1002/ijc.29467	2016	Modeling HLA associations with EBV-positive and -negative Hodgkin lymphoma suggests distinct mechanisms in disease pathogenesis.	HLA-A
25688540	10.1002/cyto.a.22643	2016	A simple flow cytometry-based barcode for routine authentication of multiple myeloma and mantle cell lymphoma cell lines.	HLA-A
25761323	10.2450/2015.0236-14	2016	Erroneous HLA typing as a result of acquired uniparental disomy in a patient with acute lymphoblastic leukaemia in peripheral blood complete remission.	HLA-A
26261988	10.1371/journal.pone.0135512	2016	HLA Allele E*01:01 Is Associated with a Reduced Risk of EBV-Related Classical Hodgkin Lymphoma Independently of HLA-A*01/*02.	HLA-A
26334430	10.1097/MPH.0000000000000419	2016	HLA Polymorphism in Algerian Children With Lymphomas.	HLA-A
26422112	10.1111/cei.12716	2016	The impact of HLA class I and EBV latency-II antigen-specific CD8(+) T cells on the pathogenesis of EBV(+) Hodgkin lymphoma.	HLA-A
27457573	10.3109/10428199109064876	2016	Prediction of Outcome in Diffuse Large Cell Lymphoma by the Major Histocompatibility Complex Class II (HLA-DR, DP, DQ) and Class I (HLA-A, B, C) Phenotype.	HLA-A
27467957	10.1080/2162402X.2016.1138199	2016	Targeting B-cell neoplasia with T-cell receptors recognizing a CD20-derived peptide on patient-specific HLA.	HLA-A
24533560	10.1111/jdv.12391	2015	Immunogenetic factors in mycosis fungoides: can the HLA system influence the susceptibility and prognosis of the disease? Long-term follow-up study of 46 patients.	HLA-A
24681846	10.1371/journal.pone.0093321	2015	Development of a T cell receptor targeting an HLA-A*0201 restricted epitope from the cancer-testis antigen SSX2 for adoptive immunotherapy of cancer.	HLA-A
24963477	10.1155/2014/231236	2015	The association of HLA-class I and class II with Hodgkin's lymphoma in Iranian patients.	HLA-A
25402415	10.1038/bmt.2014.259	2015	Alternative donors extend transplantation for patients with lymphoma who lack an HLA matched donor.	HLA-A
25414443	10.1182/blood-2014-07-587840	2015	Therapeutic targeting of the BCR-associated protein CD79b in a TCR-based approach is hampered by aberrant expression of CD79b.	HLA-A
25549594	IJIv11i4A5	2015	HLA-A*26 and susceptility of iranian patients with non-Hodgkin lymphoma.	HLA-A
25731678	10.1016/j.trim.2015.02.005	2015	HLA class I associations with EBV+ post-transplant lymphoproliferative disorder.	HLA-A
23376818	10.1038/bmt.2013.4	2014	The role of HLA-matched unrelated transplantation in adult patients with Ph chromosome-negative ALL in first remission. A decision analysis.	HLA-A
23508008	10.3324/haematol.2012.071340	2014	Immune evasion of mantle cell lymphoma: expression of B7-H1 leads to inhibited T-cell response to and killing of tumor cells.	HLA-A
23608951	10.1007/s10384-013-0244-x	2014	Clinical features of human T lymphotropic virus type 1-associated uveitis in Hokkaido, Japan.	HLA-A
23812418	10.1038/leu.2013.196	2014	Functional characterization of Foxp3-specific spontaneous immune responses.	HLA-A
23838315	10.1158/1078-0432.CCR-13-0955	2014	Generation of tumor antigen-specific T cell lines from pediatric patients with acute lymphoblastic leukemia--implications for immunotherapy.	HLA-A
24140162	10.1016/j.imlet.2013.09.011	2014	Standard therapies versus novel therapies in Hodgkin lymphoma.	HLA-A
24389072	10.1016/j.imlet.2013.12.016	2014	Universal cytotoxic activity of a HTLV-1 Tax-specific T cell clone from an HLA-A*24:02⁺ patient with adult T-cell leukemia against a variety of HTLV-I-infected T-cells.	HLA-A
24418552	10.1016/j.virol.2013.11.022	2014	HTLV-1 infects human mesenchymal stromal cell in vitro and modifies their phenotypic characteristics.	HLA-A
24448864	10.4067/S0034-98872013000800014	2014	[Allogenic hematopoietic stem cell transplantation with unrelated cord blood: report of three cases from the Chilean cord blood bank].	HLA-A
24461002	10.1111/tan.12147	2014	Ceppellini Lecture 2012: collateral damage from HLA mismatching in kidney transplantation.	HLA-A
24589652	10.3892/ijo.2014.2318	2014	The translation elongation factor eEF2 is a novel tumor‑associated antigen overexpressed in various types of cancers.	HLA-A
24824351	10.1111/bjh.12943	2014	Human heat shock protein-specific cytotoxic T lymphocytes display potent antitumour immunity in multiple myeloma.	HLA-A
25161269	10.1182/blood-2014-05-576041	2014	Nonpermissive HLA-DPB1 mismatch increases mortality after myeloablative unrelated allogeneic hematopoietic cell transplantation.	HLA-A
22343674	10.1038/bmt.2012.8	2013	Improved survival in matched unrelated donor transplant for childhood ALL since the introduction of high-resolution matching at HLA class I and II.	HLA-A
22406037	10.1016/j.bbmt.2012.01.007	2013	Comparison of outcomes after HLA-matched sibling and unrelated donor transplantation for children with high-risk acute lymphoblastic leukemia.	HLA-A
22594959	10.3109/09273948.2012.689074	2013	Birdshot retinochoroidopathy masquerading as intraocular lymphoma.	HLA-A
22759852		2013	On the aetiology of Hodgkin lymphoma.	HLA-A
22781790		2013	[The impact of HLA high resolution typing mismatching of donor-recipient pairs on outcome of unrelated donor hematopoietic stem cell transplantation].	HLA-A
22808081	10.1371/journal.pone.0039986	2013	HLA associations in classical Hodgkin lymphoma: EBV status matters.	HLA-A
22868506	10.1159/000338480	2013	Human leukocyte antigen (HLA)-DRB1*14 is associated with a high incidence of acute lymphocytic leukemia.	HLA-A
23143746	10.1007/s00262-012-1366-6	2013	Intratumoral peptide injection enhances tumor cell antigenicity recognized by cytotoxic T lymphocytes: a potential option for improvement in antigen-specific cancer immunotherapy.	HLA-A
23178241	10.1016/j.gene.2012.10.090	2013	Diagnostic utility of HFE variants in Spanish patients: association with HLA alleles and role in susceptibility to acute lymphoblastic leukemia.	HLA-A
23269992	10.1200/JCO.2012.43.6832	2013	Brentuximab vedotin combined with donor lymphocyte infusions for early relapse of Hodgkin lymphoma after allogeneic stem-cell transplantation induces tumor-specific immunity and sustained clinical remission.	HLA-A
23428979	10.2220/biomedres.34.41	2013	Establishment of a stable T lymphoma cell line transduced with HLA-A*24:02-restricted WT1-specific TCR genes and its application to antigen-specific immunomonitoring.	HLA-A
23537989	10.1016/j.gene.2013.03.040	2013	Case scenario and inquiry in response to: diagnostic utility of HFE variants in Spanish patients. Gene 2013; 514 (1): 31-35.	HLA-A
23641014	10.1182/blood-2012-11-465971	2013	Development of a novel redirected T-cell-based adoptive immunotherapy targeting human telomerase reverse transcriptase for adult T-cell leukemia.	HLA-A
23843497	10.1182/blood-2013-02-483420	2013	HLA specificities are related to development and prognosis of diffuse large B-cell lymphoma.	HLA-A
21630262	10.1002/ijc.26209	2012	T cells raised against allogeneic HLA-A2/CD20 kill primary follicular lymphoma and acute lymphoblastic leukemia cells.	HLA-A
21699878	10.1016/j.bbmt.2011.05.024	2012	Outcomes of patients treated and one human leukocyte antigen-mismatched related compared with matched unrelated donors.	HLA-A
21720136	10.1248/yakushi.131.1061	2012	[New treatment strategy for adult T-cell leukemia targeting for anti-tumor immunity and a longevity gene-encoded protein].	HLA-A
21813633	10.1158/1078-0432.CCR-11-0970	2012	Targeting human B-cell malignancies through Ig light chain-specific cytotoxic T lymphocytes.	HLA-A
21851845	10.1016/j.humimm.2011.07.308	2012	Programmed death-1 (PD-1)/PD-1 ligand pathway-mediated immune responses against human T-lymphotropic virus type 1 (HTLV-1) in HTLV-1-associated myelopathy/tropical spastic paraparesis and carriers with autoimmune disorders.	HLA-A
21894172	10.1038/icb.2011.73	2012	Immunoglobulin light chain, Blimp-1 and cytochrome P4501B1 peptides as potential vaccines for AL amyloidosis.	HLA-A
21921049	10.1182/blood-2011-04-342998	2012	Multiple HLA class I and II associations in classical Hodgkin lymphoma and EBV status defined subgroups.	HLA-A
21982422	10.1016/S1470-2045(11)70260-1	2012	Effect of donor-recipient HLA matching at HLA A, B, C, and DRB1 on outcomes after umbilical-cord blood transplantation for leukaemia and myelodysplastic syndrome: a retrospective analysis.	HLA-A
22096508	10.1371/journal.pone.0026949	2012	Variation in effects of non-Hodgkin lymphoma risk factors according to the human leukocyte antigen (HLA)-DRB1*01:01 allele and ancestral haplotype 8.1.	HLA-A
22125456	10.1100/2011/373876	2012	Human leukocyte antigen class I and II alleles and overall survival in diffuse large B-cell lymphoma and follicular lymphoma.	HLA-A
22151736	10.1186/1742-4690-8-100	2012	Functional impairment of Tax-specific but not cytomegalovirus-specific CD8+ T lymphocytes in a minor population of asymptomatic human T-cell leukemia virus type 1-carriers.	HLA-A
22160697	10.1073/pnas.1108422109	2012	Structural and energetic evidence for highly peptide-specific tumor antigen targeting via allo-MHC restriction.	HLA-A
22286212	10.1093/jnci/djr516	2012	Genome-wide association study of classical Hodgkin lymphoma and Epstein-Barr virus status-defined subgroups.	HLA-A
22340965	10.1016/S1470-2045(12)70004-9	2012	Effect of T-cell-epitope matching at HLA-DPB1 in recipients of unrelated-donor haemopoietic-cell transplantation: a retrospective study.	HLA-A
22350167	10.1007/s00251-012-0605-5	2012	Spectrum of HLA associations: the case of medically refractory pediatric acute lymphoblastic leukemia.	HLA-A
22355400	10.1371/journal.pone.0031865	2012	HLA-A*02:07 is a protective allele for EBV negative and a susceptibility allele for EBV positive classical Hodgkin lymphoma in China.	HLA-A
22489945	10.1111/j.1399-0039.2012.01868.x	2012	Somatic mutations in the HLA genes of patients with hematological malignancy.	HLA-A
22645177	10.1182/blood-2011-09-382838	2012	TCL1: a shared tumor-associated antigen for immunotherapy against B-cell lymphomas.	HLA-A
22705988	10.1158/1078-0432.CCR-12-0763	2012	IGKV3 proteins as candidate off-the-shelf vaccines for kappa-light chain-restricted B-cell non-Hodgkin lymphomas.	HLA-A
22708687	10.1111/j.1399-0039.2012.01914.x	2012	Identification of A*02:336 in a Mexican Mestizo acute lymphoblastic leukemia patient from the state of Veracruz.	HLA-A
20536911	10.1111/j.1432-2277.2010.01117.x	2011	Impact of amino acid substitution at residue 9 of HLA-A2 on the development of acute GVHD in Korean pediatric patients receiving unrelated hematopoietic stem cell transplantation.	HLA-A
20674756	10.1016/j.bbmt.2010.07.022	2011	One-antigen mismatched related versus HLA-matched unrelated donor hematopoietic stem cell transplantation in adults with acute leukemia: Center for International Blood and Marrow Transplant Research results in the era of molecular HLA typing.	HLA-A
20719985	10.1128/CVI.00189-10	2011	Monofunctional and polyfunctional CD8+ T cell responses to human herpesvirus 8 lytic and latency proteins.	HLA-A
20870028	10.1016/j.bbmt.2010.09.012	2011	HLA-C antigen mismatch is associated with worse outcome in unrelated donor peripheral blood stem cell transplantation.	HLA-A
21059899	10.1182/blood-2010-08-301598	2011	MHC variation and risk of childhood B-cell precursor acute lymphoblastic leukemia.	HLA-A
21159666	10.1158/0008-5472.CAN-10-1296	2011	Molecular mechanism of MART-1+/A*0201+ human melanoma resistance to specific CTL-killing despite functional tumor-CTL interaction.	HLA-A
21229399	10.1007/s12185-010-0758-7	2011	Activation of T-cell receptor signaling in peripheral T-cell lymphoma cells plays an important role in the development of lymphoma-associated hemophagocytosis.	HLA-A
21264872	10.1002/jmv.21985	2011	Target epitopes of HTLV-1 recognized by class I MHC-restricted cytotoxic T lymphocytes in patients with myelopathy and spastic paraparesis and infected patients with autoimmune disorders.	HLA-A
21275963	10.1111/j.1365-2141.2010.08531.x	2011	No association of HLA-A supertype with outcome in childhood acute lymphoblastic leukaemia: results of the UKALL XI trial.	HLA-A
21332943	10.1111/j.1742-4658.2011.08055.x	2011	Oligomannose-coated liposomes efficiently induce human T-cell leukemia virus-1-specific cytotoxic T lymphocytes without adjuvant.	HLA-A
21657960	10.3109/10428194.2011.577257	2011	Vaccination with immunoglobulin frame region-derived nonapeptide elicits cellular immune response against lymphoma in human leukocyte antigen-A2.1 transgenic mice.	HLA-A
22030472	10.1016/j.cellimm.2011.10.002	2011	Advantage of higher-avidity CTL specific for Tax against human T-lymphotropic virus-1 infected cells and tumors.	HLA-A
15624334		2010	[Activation of macrophages from lymphoma-bearing mice by liposome mediated intraperitoneal IL-2 and IL-6 gene therapy].	HLA-A
19703232	10.1111/j.1744-313X.2009.00872.x	2010	Confirmation of allele HLA-A*3116 found in a family of a leukaemia patient with Caucasian and Caribbean origin.	HLA-A
19741723	10.1038/leu.2009.184	2010	Identification of native, immunogenic peptides from Cyclin D1.	HLA-A
19903903	10.1182/blood-2009-07-233270	2010	Autoimmune B-cell lymphopenia after successful adoptive therapy with telomerase-specific T lymphocytes.	HLA-A
19922423	10.1111/j.1365-2567.2009.03190.x	2010	Characterization of an human leucocyte antigen A2-restricted Epstein-Barr virus nuclear antigen-1-derived cytotoxic T-lymphocyte epitope.	HLA-A
20110857	10.1097/TP.0b013e3181c69855	2010	Impact of HLA mismatching on incidence of posttransplant non-hodgkin lymphoma after kidney transplantation.	HLA-A
20146028	10.1007/s12185-010-0509-9	2010	Outcome of allogeneic bone marrow transplantation from unrelated donors for adult Philadelphia chromosome-negative acute lymphocytic leukemia in first complete-remission.	HLA-A
20147981	10.1038/leu.2010.17	2010	Human leukocyte antigen (HLA) A1-B8-DR3 (8.1) haplotype, tumor necrosis factor (TNF) G-308A, and risk of non-Hodgkin lymphoma.	HLA-A
20308568	10.1073/pnas.0915054107	2010	HLA-A alleles and infectious mononucleosis suggest a critical role for cytotoxic T-cell response in EBV-related Hodgkin lymphoma.	HLA-A
20385791	10.1182/blood-2010-01-266775	2010	Human leukocyte antigen class I and II alleles in non-Hodgkin lymphoma etiology.	HLA-A
20388056	10.3109/10428191003802340	2010	Human leukocyte antigen class I alleles and the risk of chronic myelogenous leukemia: a meta-analysis.	HLA-A
20422411	10.1007/s00262-010-0845-x	2010	Antitumor cytotoxic T-cell response induced by a survivin peptide mimic.	HLA-A
20426540	10.1080/0032472031000141284	2010	Long-term outcome of a phase II study of BM transplants, partially depleted ex-vivo of CD5-positive and CD8-positive T-lymphocytes in unrelated and related donor 1 antigen mismatched recipients.	HLA-A
20522710	10.1182/blood-2010-02-270199	2010	Comparative analysis of predicted HLA binding of immunoglobulin idiotype sequences indicates T cell-mediated immunosurveillance in follicular lymphoma.	HLA-A
20548266	10.1097/TP.0b013e3181e46a22	2010	Pediatric kidney transplantation: analysis of donor age, HLA match, and posttransplant non-Hodgkin lymphoma: a collaborative transplant study report.	HLA-A
20558104	10.1016/S1470-2045(10)70127-3	2010	Effect of graft source on unrelated donor haemopoietic stem-cell transplantation in adults with acute leukaemia: a retrospective analysis.	HLA-A
20647322	10.1158/0008-5472.CAN-10-0678	2010	Single-cell analysis of T-cell receptor repertoire of HTLV-1 Tax-specific cytotoxic T cells in allogeneic transplant recipients with adult T-cell leukemia/lymphoma.	HLA-A
20861911	10.1038/leu.2010.196	2010	DNA vaccines to target the cancer testis antigen PASD1 in human multiple myeloma.	HLA-A
16383233		2009	[Function analysis of the family-specific CTL induced by peptides derived from IgHV gene framework region of B-cell malignance].	HLA-A
18544086	10.1111/j.1365-2141.2008.07177.x	2009	Impact of HLA-DPB1 allelic and single amino acid mismatches on HSCT.	HLA-A
18583252		2009	[Association of HLA-A, B and DRB1 alleles with leukemia in Han population in Hunan Province].	HLA-A
18809757	10.1182/blood-2008-06-165654	2009	Vaccination with autologous tumor-loaded dendritic cells induces clinical and immunologic responses in indolent B-cell lymphoma patients with relapsed and measurable disease: a pilot study.	HLA-A
18841361	10.1007/s00262-008-0601-7	2009	Role of the inhibitory KIR ligand HLA-Bw4 and HLA-C expression levels in the recognition of leukemic cells by Natural Killer cells.	HLA-A
18988867	10.1182/blood-2008-03-144071	2009	Ex vivo characterization of polyclonal memory CD8+ T-cell responses to PRAME-specific peptides in patients with acute lymphoblastic leukemia and acute and chronic myeloid leukemia.	HLA-A
19167686	10.1016/j.bbmt.2008.11.025	2009	Treatment of acute leukemia with unmanipulated HLA-mismatched/haploidentical blood and bone marrow transplantation.	HLA-A
19184004	10.1007/s00262-009-0657-z	2009	Amyloid precursor-like protein 2 association with HLA class I molecules.	HLA-A
19188166	10.1158/1078-0432.CCR-08-1823	2009	Human-like mouse models for testing the efficacy and safety of anti-beta2-microglobulin monoclonal antibodies to treat myeloma.	HLA-A
19197722	10.1080/10428190802578478	2009	Enhancement of lytic activity of leukemic cells by CD8+ cytotoxic T lymphocytes generated against a WT1 peptide analogue.	HLA-A
19199259	10.3760/cma.j.issn.1003-9406.2009.01.019	2009	[Analysis of HLA haplotype frequency and linkage disequilibrium in patients with acute lymphoblastic leukemia from Northern Chinese Han].	HLA-A
19225534	10.1038/leu.2009.19	2009	Cyclin D1 as a universally expressed mantle cell lymphoma-associated tumor antigen for immunotherapy.	HLA-A
19235017	10.1080/10428190802668873	2009	HLA risk markers for chronic myelogenous leukemia in Eastern Canada.	HLA-A
19265139	10.4049/jimmunol.0802316	2009	Class I HLA folding and antigen presentation in beta 2-microglobulin-defective Daudi cells.	HLA-A
19342968	10.1097/CJI.0b013e31819d4e09	2009	Identification of an immunogenic HLA-A*0201-binding T-cell epitope of the transcription factor PAX2.	HLA-A
19493232	10.1111/j.1399-0039.2009.01235.x	2009	Killer immunoglobulin-like receptors (KIR2DL2 and/or KIR2DS2) in presence of their ligand (HLA-C1 group) protect against chronic myeloid leukaemia.	HLA-A
19552722	10.1111/j.1365-2141.2009.07761.x	2009	Cytolytic T-cell response to the PASD1 cancer testis antigen in patients with diffuse large B-cell lymphoma.	HLA-A
19587004	10.4049/jimmunol.0803441	2009	Processing of two latent membrane protein 1 MHC class I epitopes requires tripeptidyl peptidase II involvement.	HLA-A
19889459	10.1016/j.molimm.2009.09.006	2009	Efficient induction of human T-cell leukemia virus-1-specific CTL by chimeric particle without adjuvant as a prophylactic for adult T-cell leukemia.	HLA-A
15854278		2008	[Study on the correlation between acute lymphoblastic leukemia and HLA genes in southern China Han population].	HLA-A
17665074	10.1590/s0104-42302007000300024	2008	[Association between HLA and leukemia in a mixed Brazilian population].	HLA-A
17926184	10.1080/10428190701632830	2008	Human leukocyte antigens in 295 Chinese patients with chronic myeloid leukemia.	HLA-A
17971052	10.1111/j.1399-0039.2007.00954.x	2008	Haplotype-specific pattern of association of human major histocompatibility complex with non-Hodgkin's lymphoma outcome.	HLA-A
18005680	10.1016/j.chom.2007.01.001	2008	A two-pronged mechanism for HIV-1 Nef-mediated endocytosis of immune costimulatory molecules CD80 and CD86.	HLA-A
18253030	10.1159/000112062	2008	U-HO1, a new cell line derived from a primary refractory classical Hodgkin lymphoma.	HLA-A
18257895	10.1111/j.1399-0039.2008.01005.x	2008	HLA-G protein expression as a potential immune escape mechanism in classical Hodgkin's lymphoma.	HLA-A
18301962	10.1007/s12185-008-0040-4	2008	Association of HLA alleles with non-Hodgkin's lymphoma in Korean population.	HLA-A
18305579	10.1038/sj.gt.3303078	2008	Retroviral transfer of a dominant TCR prevents surface expression of a large proportion of the endogenous TCR repertoire in human T cells.	HLA-A
18398747	10.1080/10428190801911688	2008	Cellular immune responses against the cancer-testis antigen SPAN-XB in healthy donors and patients with multiple myeloma.	HLA-A
18481383	10.1097/CJI.0b013e31815b69c8	2008	Chemotherapeutic drugs may be used to enhance the killing efficacy of human tumor antigen peptide-specific CTLs.	HLA-A
18545249	10.1038/bmt.2008.59	2008	Strategies of the donor search for children with second CR ALL lacking a matched sibling donor.	HLA-A
18587537	10.1007/s11060-008-9630-5	2008	Primary CNS lymphoma and HLA class I and II alleles in a German cohort of immunocompetent patients.	HLA-A
18724291	10.1038/bmt.2008.145	2008	Current status of hematopoietic stem cell transplantations in Vietnam.	HLA-A
18779413	10.1182/blood-2008-06-162883	2008	A mechanism for the HLA-A*01-associated risk for EBV+ Hodgkin lymphoma and infectious mononucleosis.	HLA-A
18927298	10.1158/1078-0432.CCR-08-0825	2008	Cyclin D1-specific cytotoxic T lymphocytes are present in the repertoire of cancer patients: implications for cancer immunotherapy.	HLA-A
16710717	10.1007/s00277-006-0118-0	2007	HLA-B67 may be a male-specific HLA marker of susceptibility to relapsed childhood ALL in Hong Kong Chinese and HLA-A33 or HLA-B17 signifies a higher presentation leukocytosis: A retrospective analysis on 53 transplant candidates (1989-2003).	HLA-A
16718496	10.1007/s00277-006-0137-x	2007	Identification and characterization of HLA-class-I-restricted T-cell epitopes in the putative tumor-associated antigens P21-activated serin kinase 2 (PAK2) and cyclin-dependent kinase inhibitor 1A (CDKN1A).	HLA-A
16923577	10.1080/10428190600580858	2007	High proviral load of human T-lymphotropic virus type I in patients with myelodysplastic syndrome carrying HLA-A26.	HLA-A
17015761	10.4049/jimmunol.177.8.5718	2007	Reduced frequency, diversity, and function of human T cell leukemia virus type 1-specific CD8+ T cell in adult T cell leukemia patients.	HLA-A
17089123	10.1007/s00262-006-0239-2	2007	Immunoscreening of a cutaneous T-cell lymphoma library for plasma membrane proteins.	HLA-A
17119058	10.1158/1055-9965.EPI-06-0476	2007	The human leukocyte antigen class I region is associated with EBV-positive Hodgkin's lymphoma: HLA-A and HLA complex group 9 are putative candidate genes.	HLA-A
17142956	10.3960/jslrt.46.67	2007	A family predisposition to adult T-cell leukemia.	HLA-A
17145860	10.1158/0008-5472.CAN-06-2326	2007	Isolation of germ cells from leukemia and lymphoma cells in a human in vitro model: potential clinical application for restoring human fertility after anticancer therapy.	HLA-A
17182178	10.1016/j.canlet.2006.11.004	2007	Identification of an HLA-A*0201 restricted Bcl2-derived epitope expressed on tumors.	HLA-A
17241929	10.1016/j.bbmt.2006.10.005	2007	Intravenous busulfan and melphalan, tacrolimus, and short-course methotrexate followed by unmodified HLA-matched related or unrelated hematopoietic stem cell transplantation for the treatment of advanced hematologic malignancies.	HLA-A
17302780	10.1111/j.1537-2995.2007.01109.x	2007	A possible role for the production of multiple HLA antibodies in fatal platelet transfusion refractoriness after peripheral blood progenitor cell transplantation from the mother in a patient with relapsed leukemia.	HLA-A
17311253	10.1002/gcc.20436	2007	Association of human leukocyte antigen ancestral haplotype 8.1 with adverse outcome of non-Hodgkin's lymphoma.	HLA-A
17437273	10.1002/ijc.22767	2007	Risk of human T-lymphotropic virus type I-associated diseases in Jamaica with common HLA types.	HLA-A
17505014	10.1182/blood-2007-03-076844	2007	Graft-versus-leukemia effects associated with detectable Wilms tumor-1 specific T lymphocytes after allogeneic stem-cell transplantation for acute lymphoblastic leukemia.	HLA-A
17515399	10.1182/blood-2007-03-082529	2007	Dickkopf-1 (DKK1) is a widely expressed and potent tumor-associated antigen in multiple myeloma.	HLA-A
17516523	10.1002/jmv.20807	2007	Anti-HTLV-1 tax antibody and tax-specific cytotoxic T lymphocyte are associated with a reduction in HTLV-1 proviral load in asymptomatic carriers.	HLA-A
17517179		2007	Generation of cytotoxic T lymphocytes specific for B-cell acute lymphoblastic leukemia family-shared peptides derived from immunoglobulin heavy chain framework region.	HLA-A
17545610	10.1158/0008-5472.CAN-06-3737	2007	Alternative BCR/ABL splice variants in Philadelphia chromosome-positive leukemias result in novel tumor-specific fusion proteins that may represent potential targets for immunotherapy approaches.	HLA-A
17560447	10.1016/S0140-6736(07)60915-5	2007	Outcomes of transplantation of unrelated donor umbilical cord blood and bone marrow in children with acute leukaemia: a comparison study.	HLA-A
17626842	10.1182/blood-2006-11-058750	2007	Allorestricted T cells with specificity for the FMNL1-derived peptide PP2 have potent antitumor activity against hematologic and other malignancies.	HLA-A
17627756	10.1111/j.1744-313X.2007.00691.x	2007	A novel HLA-A*29 allele (A*2916) of a Caucasian relative to an ALL patient containing a point mutation in a putatively conserved region which was identified through the loss of a specific amplificate in a low-resolution SSP-PCR kit.	HLA-A
17630352	10.1182/blood-2007-05-086934	2007	HLA-A*02 is associated with a reduced risk and HLA-A*01 with an increased risk of developing EBV+ Hodgkin lymphoma.	HLA-A
17909631	10.1172/JCI32377	2007	HLA class I polymorphisms are associated with development of infectious mononucleosis upon primary EBV infection.	HLA-A
16061026		2006	[The characteristics of anti-B-cell malignance cytotoxic T lymphocytic clones induced by lymphoma relative peptides].	HLA-A
16114011	10.1002/ijc.21410	2006	B and CTL responses to the ALK protein in patients with ALK-positive ALCL.	HLA-A
16257267	10.1016/j.clim.2005.09.006	2006	HLA B44 is associated with decreased severity of autoimmune lymphoproliferative syndrome in patients with CD95 defects (ALPS type Ia).	HLA-A
16305691	10.1111/j.1399-0039.2005.00487.x	2006	A novel HLA-A*2601 variant, A*260102, identified by sequence-based typing.	HLA-A
16307660	10.1111/j.1365-2133.2005.06877.x	2006	Pathogenetic mechanisms of vitiligo in a patient with Sézary syndrome.	HLA-A
16321860	10.1080/10428190500287117	2006	Human leukocyte antigens in Indian patients with chronic myeloid leukemia.	HLA-A
16321862	10.1080/10428190500301306	2006	Flt3-ITD mutations can generate leukaemia specific neoepitopes: potential role for immunotherapeutic approaches.	HLA-A
16339578	10.4049/jimmunol.175.12.8365	2006	CD8+ T cell-mediated HLA-A*0201-restricted cytotoxicity to transaldolase peptide 168-176 in patients with multiple sclerosis.	HLA-A
16412018	10.1111/j.1365-2141.2005.05861.x	2006	Analysis of the intraclonal diversity of HLA-A0201-restricted T lymphocyte epitopes in follicular lymphoma idiotype.	HLA-A
16418800	10.1007/s10875-006-6532-1	2006	Transduction of primary lymphocytes with Epstein-Barr virus (EBV) latent membrane protein-specific T-cell receptor induces lysis of virus-infected cells: A novel strategy for the treatment of Hodgkin's disease and nasopharyngeal carcinoma.	HLA-A
16479544	10.1002/eji.200535485	2006	Epstein-Barr virus (EBV) latent membrane protein-1-specific cytotoxic T lymphocytes targeting EBV-carrying natural killer cell malignancies.	HLA-A
16518539	10.1111/j.1745-7270.2006.00150.x	2006	Induction of the Epstein-Barr virus latent membrane protein 2 antigen-specific cytotoxic T lymphocytes using human leukocyte antigen tetramer-based artificial antigen-presenting cells.	HLA-A
16596644	10.1002/ijc.21960	2006	Monitoring of WT1-specific cytotoxic T lymphocytes after allogeneic hematopoietic stem cell transplantation.	HLA-A
16707474	10.1158/0008-5472.CAN-05-4018	2006	Vaccination with human HER-2/neu (435-443) CTL peptide induces effective antitumor immunity against HER-2/neu-expressing tumor cells in vivo.	HLA-A
16858680	10.1002/ijc.22113	2006	Identification of HLA class I dependent immunogenic peptides from clonotypic TCRbeta expressed in cutaneous T-cell lymphoma.	HLA-A
17032500	10.1593/neo.06415	2006	Tumor mRNA-transfected dendritic cells stimulate the generation of CTL that recognize neuroblastoma-associated antigens and kill tumor cells: immunotherapeutic implications.	HLA-A
15235393	10.1097/00002371-200407000-00008	2005	The generation and characterization of LMP2-specific CTLs for use as adoptive transfer from patients with relapsed EBV-positive Hodgkin disease.	HLA-A
15367432	10.1182/blood-2004-07-2548	2005	Immunogenicity of Bcl-2 in patients with cancer.	HLA-A
15375491		2005	Recognition of Epstein-Barr virus-associated gastric carcinoma cells by cytotoxic T lymphocytes induced in vitro with autologous lymphoblastoid cell line and LMP2-derived, HLA-A24-restricted 9-mer peptide.	HLA-A
15621808	10.1080/10428190400013589	2005	Two new cases of familial hairy cell leukemia associated with HLA haplotypes A2, B7, Bw4, Bw6.	HLA-A
15646657	10.1532/ijh97.04109	2005	Reconstitution of HLA-A*2402-restricted cytomegalovirus-specific T-cells following stem cell transplantation.	HLA-A
15682076	10.1016/j.bbmt.2004.11.020	2005	Umbilical cord blood transplantation in adults: results of the prospective Cord Blood Transplantation (COBLT).	HLA-A
15688394	10.1002/ijc.20906	2005	Identification of a new HLA-A*0201-restricted cryptic epitope from CYP1B1.	HLA-A
15746068	10.1158/1078-0432.CCR-04-1612	2005	Identification of CD19 and CD20 peptides for induction of antigen-specific CTLs against B-cell malignancies.	HLA-A
15889252	10.1007/s00262-005-0696-z	2005	Induction of anti B-cell malignance CTL response by subfamily-shared peptides derived from variable domain of immunoglobulin heavy chain.	HLA-A
15916683	10.1111/j.1365-2141.2005.05499.x	2005	Epstein-Barr virus-associated familial Hodgkin lymphoma: paediatric onset in three of five siblings.	HLA-A
15946551		2005	[Epitopes recognized by cytotoxic T lymphocytes in immunoglobulin heavy chain variable regions expressed by B-cell acute lymphoblastic leukemia].	HLA-A
16007866	10.1111/j.1600-0609.2005.00452.x	2005	Genetic susceptibility to Hodgkin's lymphoma associated with the human leukocyte antigen region.	HLA-A
16014972	10.1128/JVI.79.15.10088-10092.2005	2005	Identification of two new HLA-A*1101-restricted tax epitopes recognized by cytotoxic T lymphocytes in an adult T-cell leukemia patient after hematopoietic stem cell transplantation.	HLA-A
16042692	10.1111/j.1365-2141.2005.05604.x	2005	Identification of APOBEC3B as a potential target for the graft-versus-lymphoma effect by SEREX in a patient with mantle cell lymphoma.	HLA-A
16148164	10.4049/jimmunol.175.6.4137	2005	Characterization of latent membrane protein 2 specificity in CTL lines from patients with EBV-positive nasopharyngeal carcinoma and lymphoma.	HLA-A
16204693	10.1093/jnci/dji188	2005	5-fluorouracil-based chemotherapy enhances the antitumor activity of a thymidylate synthase-directed polyepitopic peptide vaccine.	HLA-A
16267031	10.1158/0008-5472.CAN-05-1574	2005	Gene expression profiling identifies BAX-delta as a novel tumor antigen in acute lymphoblastic leukemia.	HLA-A
12869512	10.1182/blood-2003-01-0198	2004	Induction of cytotoxic T-cell responses against the oncofetal antigen-immature laminin receptor for the treatment of hematologic malignancies.	HLA-A
12960136		2004	Expression of her-2/neu on acute lymphoblastic leukemias: implications for the development of immunotherapeutic approaches.	HLA-A
14523467	10.1038/sj.leu.2403150	2004	DNA sequencing-based HLA typing detects a B-cell ALL blast-specific mutation in HLA-A(*)2402 resulting in loss of HLA allele expression.	HLA-A
14574331	10.1038/sj.leu.2403176	2004	Loss of the ex vivo but not the reinducible CD8+ T-cell response to Tax in human T-cell leukemia virus type 1-infected patients with adult T-cell leukemia/lymphoma.	HLA-A
14689875		2004	[Acute lymphoblastic leukemia in childhood treated with non-T-cell depleted bone marrow transplantation from an HLA 2 loci (HLA-A and-DRB1)-mismatched mother after early graft failure of cord blood transplantation].	HLA-A
14727382		2004	[Association of HLA class I and leukemia in mestizo patients of the state of Zulia, Venezuela].	HLA-A
14871984	10.1158/1078-0432.ccr-03-0075	2004	Autoreactive, cytotoxic T lymphocytes specific for peptides derived from normal B-cell differentiation antigens in healthy individuals and patients with B-cell malignancies.	HLA-A
14990068		2004	[Characteristics of immunoglobulin heavy chain variable region genes in childhood B-cell acute lymphoblastic leukemia].	HLA-A
14990121		2004	[Proliferation of specific cytotoxic T lymphocytes induced by immunoglobulin heavy chain framework region-derived antigenic nonapeptides].	HLA-A
15202948	10.1186/1471-2407-4-25	2004	Association of HLA Class I and Class II genes with bcr-abl transcripts in leukemia patients with t(9;22) (q34;q11).	HLA-A
15367598	10.1128/JVI.78.19.10320-10327.2004	2004	Direct evidence for a chronic CD8+-T-cell-mediated immune reaction to tax within the muscle of a human T-cell leukemia/lymphoma virus type 1-infected patient with sporadic inclusion body myositis.	HLA-A
15384976	10.1111/j.1365-2141.2004.05151.x	2004	Loss of heterozygosity, a frequent but a non-exclusive mechanism responsible for HLA dysregulation in non-Hodgkin's lymphomas.	HLA-A
12002748	10.1080/10428190290011930	2003	Hemochromatosis gene in leukemia and lymphoma.	HLA-A
12411306	10.1182/blood-2002-05-1514	2003	Generating CTLs against the subdominant Epstein-Barr virus LMP1 antigen for the adoptive immunotherapy of EBV-associated malignancies.	HLA-A
12468425	10.1182/blood-2002-10-3092	2003	Therapeutic LMP1 polyepitope vaccine for EBV-associated Hodgkin disease and nasopharyngeal carcinoma.	HLA-A
12473604		2003	Screening of HLA-A24-restricted epitope peptides from prostate-specific membrane antigen that induce specific antitumor cytotoxic T lymphocytes.	HLA-A
12537978	10.1016/s0145-2126(02)00092-9	2003	The in vitro generation of Ph1+ ALL-specific HLA-A24-restricted cytotoxic T lymphocytes using a synthetic 16 mer minor bcr-abl peptide.	HLA-A
12584045	10.1016/s1521-6616(02)00016-5	2003	Induction of immunity to tumor-associated antigens following dendritic cell vaccination of cancer patients.	HLA-A
12594285	10.4049/jimmunol.170.5.2582	2003	CD8-independent tumor cell recognition is a property of the T cell receptor and not the T cell.	HLA-A
12688312	10.1080/1042819021000035725	2003	Preferentially expressed antigen of melanoma (PRAME) in the development of diagnostic and therapeutic methods for hematological malignancies.	HLA-A
12791654	10.1182/blood-2003-02-0482	2003	HLA-matched unrelated donor hematopoietic cell transplantation after nonmyeloablative conditioning for patients with hematologic malignancies.	HLA-A
12928425	10.4049/jimmunol.171.5.2714	2003	Definition of TCR epitopes for CTL-mediated attack of cutaneous T cell lymphoma.	HLA-A
12970797	10.1038/sj.leu.2403064	2003	Association of acute leukemia and autoimmune polyendocrine syndrome in two kindreds.	HLA-A
14515258	10.1002/eji.200324182	2003	Differential effects of US2, US6 and US11 human cytomegalovirus proteins on HLA class Ia and HLA-E expression: impact on target susceptibility to NK cell subsets.	HLA-A
11587218	10.1038/sj.leu.2402273	2002	An optimised biphasic culture system for the generation of functional dendritic cells from patients with acute lymphoblastic leukaemia at presentation and in clinical remission.	HLA-A
11808079		2002	[Successful donor lymphocyte infusion for Epstein-Barr virus-associated lymphoproliferative disorder after allogeneic bone marrow transplantation from an HLA 1-locus-mismatched sibling donor in a patient with acute lymphocytic leukemia].	HLA-A
11872238	10.1016/s0198-8859(01)00381-0	2002	Loss or downregulation of HLA class I expression at the allelic level in acute leukemia is infrequent but functionally relevant, and can be restored by interferon.	HLA-A
11877285	10.1182/blood.v99.6.2100	2002	ALK as a novel lymphoma-associated tumor antigen: identification of 2 HLA-A2.1-restricted CD8+ T-cell epitopes.	HLA-A
11917131	10.1073/pnas.072495599	2002	MYC overexpression imposes a nonimmunogenic phenotype on Epstein-Barr virus-infected B cells.	HLA-A
12010826	10.1182/blood.v99.11.4200	2002	The clinical significance of human leukocyte antigen (HLA) allele compatibility in patients receiving a marrow transplant from serologically HLA-A, HLA-B, and HLA-DR matched unrelated donors.	HLA-A
12100728	10.1046/j.1365-2567.2002.01424.x	2002	Identification of cytotoxic T lymphocyte epitopes of human herpesvirus 8.	HLA-A
12352909	10.1097/00007890-200208270-00012	2002	Identification of Epstein-Barr virus-specific CD8+ T lymphocytes in the circulation of pediatric transplant recipients.	HLA-A
12399966	10.1038/sj.leu.2402690	2002	Improvement over time in outcome for children with acute lymphoblastic leukemia in second remission given hematopoietic stem cell transplantation from unrelated donors.	HLA-A
12412391		2002	Unrelated donor marrow transplantation in childhood: a report from the Associazione Italiana Ematologia e Oncologia Pediatrica (AIEOP) and the Gruppo Italiano per il Trapianto Midollo Osseo (GITMO).	HLA-A
11071656		2001	Extensive genetic alterations of the HLA region, including homozygous deletions of HLA class II genes in B-cell lymphomas arising in immune-privileged sites.	HLA-A
11121132	10.1046/j.1523-1747.2000.00195.x	2001	Functional inhibitory receptors expressed by a cutaneous T cell lymphoma-specific cytolytic clonal T cell population.	HLA-A
11159505	10.1182/blood.v97.4.835	2001	An Epstein-Barr virus deletion mutant associated with fatal lymphoproliferative disease unresponsive to therapy with virus-specific CTLs.	HLA-A
11159527	10.1182/blood.v97.4.987	2001	Existence of escape mutant in HTLV-I tax during the development of adult T-cell leukemia.	HLA-A
11161978	10.1006/clim.2000.4977	2001	Retroviral transduction of a T cell receptor specific for an Epstein-Barr virus-encoded peptide.	HLA-A
11169449	10.1002/1521-4141(200101)31:1&lt;156::aid-immu156&gt;3.0.co;2-p	2001	Mimotopes for tumor-specific T lymphocytes in human cancer determined with combinatorial peptide libraries.	HLA-A
11207288	10.4049/jimmunol.166.5.3324	2001	At least one class I gene in restriction fragment pattern-Y (Rfp-Y), the second MHC gene cluster in the chicken, is transcribed, polymorphic, and shows divergent specialization in antigen binding region.	HLA-A
11291070	10.1002/ijc.1211	2001	MedB-1, a human tumor cell line derived from a primary mediastinal large B-cell lymphoma.	HLA-A
11401086	10.1007/s002770000269	2001	Anti-thymocyte-globulin as part of the preparative regimen prevents graft failure and severe graft versus host disease (GvHD) in allogeneic stem cell transplantation from unrelated donors.	HLA-A
11431353		2001	Somatically mutated regions of immunoglobulin on human B-cell lymphomas code for peptides that bind to autologous major histocompatibility complex class I, providing a potential target for cytotoxic T cells.	HLA-A
11458816	10.1081/cnv-100103847	2001	Human leukocyte antigens (HLA)-Cw as prognostic indicators in autologous transplantation for lymphoma.	HLA-A
11485622	10.1089/088922201300343735	2001	HLA-A*26, HLA-B*4002, HLA-B*4006, and HLA-B*4801 alleles predispose to adult T cell leukemia: the limited recognition of HTLV type 1 tax peptide anchor motifs and epitopes to generate anti-HTLV type 1 tax CD8(+) cytotoxic T lymphocytes.	HLA-A
11559560		2001	The epithelial tumor antigen MUC1 is expressed in hematological malignancies and is recognized by MUC1-specific cytotoxic T-lymphocytes.	HLA-A
11698283	10.1182/blood.v98.10.2999	2001	Induction of cytotoxic T-cell responses against immunoglobulin V region-derived peptides modified at human leukocyte antigen-A2 binding residues.	HLA-A
10607714		2000	HLA class I-restricted lysis of leukemia cells by a CD8(+) cytotoxic T-lymphocyte clone specific for WT1 peptide.	HLA-A
10715516	10.1016/s0198-8859(99)00186-x	2000	Differential expression of human major histocompatibility class I loci: HLA-A, -B, and -C.	HLA-A
10737389	10.1054/bjoc.1999.1042	2000	Sensitization of tumour cells to lysis by virus-specific CTL using antibody-targeted MHC class I/peptide complexes.	HLA-A
10835683	10.1038/76243	2000	Immunoglobulin framework-derived peptides function as cytotoxic T-cell epitopes commonly expressed in B-cell malignancies.	HLA-A
10861473		2000	Low frequency of HLA-A*0201 allele in patients with Epstein-Barr virus-positive nasal lymphomas with polymorphic reticulosis morphology.	HLA-A
11002759	10.1136/jcp.53.8.581	2000	HTLV-1 infections.	HLA-A
10026877	10.1007/978-1-4615-5357-1_36	1999	Identification of epitopes for CTCL-specific cytotoxic T lymphocytes.	HLA-A
10347989	10.1016/S0140-6736(98)11135-2	1999	Mixed lymphohaemopoietic chimerism and graft-versus-lymphoma effects after non-myeloablative therapy and HLA-mismatched bone-marrow transplantation.	HLA-A
10395112	10.1034/j.1399-0039.1999.530612.x	1999	Identification of an HLA-A11 serological variant and its characterization by sequencing based typing.	HLA-A
10417757	10.1002/(sici)1097-0215(19990827)82:5&lt;630::aid-ijc2&gt;3.0.co;2-d	1999	HLA-A alleles of patients with pyothorax-associated lymphoma: anti-Epstein-Barr virus (EBV) host immune responses during the development of EBV latent antigen-positive lymphomas.	HLA-A
10487851	10.1016/S0002-9440(10)65193-0	1999	Epstein-Barr virus (EBV) nuclear antigen (EBNA)-4 mutation in EBV-associated malignancies in three different populations.	HLA-A
10498594		1999	Children with acute lymphoblastic leukemia who receive T-cell-depleted HLA mismatched marrow allografts from unrelated donors have an increased incidence of primary graft failure but a similar overall transplant outcome.	HLA-A
10566592	10.1016/s0198-8859(99)00076-2	1999	Acquisition of a stimulatory activity for Vgamma9/Vdelta2 T cells by a Burkitt's lymphoma cell line without loss of HLA class I expression.	HLA-A
9935237	10.1002/(sici)1097-0215(19990105)80:1&lt;92::aid-ijc18&gt;3.0.co;2-m	1999	Identification of HLA-A24 epitope peptides of carcinoembryonic antigen which induce tumor-reactive cytotoxic T lymphocyte.	HLA-A
9489758	10.1016/s0963-6897(97)00004-3	1998	Generation of primary peptide-specific CD8+ cytotoxic T-lymphocytes in vitro using allogeneic dendritic cells.	HLA-A
9508175	10.1200/JCO.1998.16.3.931	1998	Unrelated donor bone marrow transplantation for children and adolescents with Philadelphia-positive acute lymphoblastic leukemia.	HLA-A
9521052	10.1002/(SICI)1521-4141(199802)28:02&lt;451::AID-IMMU451&gt;3.0.CO;2-U	1998	Identification of cytotoxic T cell epitopes within Epstein-Barr virus (EBV) oncogene latent membrane protein 1 (LMP1): evidence for HLA A2 supertype-restricted immune recognition of EBV-infected cells by LMP1-specific cytotoxic T lymphocytes.	HLA-A
9575394		1998	Risk factors in bone marrow transplant recipients with leukaemia. Increased relapse risk in patients treated with ciprofloxacin for gut decontamination.	HLA-A
9606876		1998	[Connection between Epstein-Barr virus infection and HLA phenotype and features of cytokine status in patients with non-Hodgkin's lymphomas].	HLA-A
9658107	10.1128/JVI.72.8.6614-6620.1998	1998	Identification of a cytotoxic T-lymphocyte response to the novel BARF0 protein of Epstein-Barr virus: a critical role for antigen expression.	HLA-A
9664088	10.1172/JCI3126	1998	Cytotoxic T cell response against the chimeric ETV6-AML1 protein in childhood acute lymphoblastic leukemia.	HLA-A
9707019	10.1038/sj.bmt.1701298	1998	Faster neutrophil and platelet engraftment, but no differences in acute GVHD or survival, using peripheral blood stem cells from related and unrelated donors, compared to bone marrow.	HLA-A
9722075	10.1038/sj.bmt.1701336	1998	Acute graft-versus-host disease after bone marrow transplantation with a single HLA-DPB1*1001 mismatch: involvement of different TCRBV subsets.	HLA-A
9742638		1998	[The factors of hereditary predisposition to lymphogranulomatosis].	HLA-A
9746788		1998	Analysis of major histocompatibility complex class I, TAP expression, and LMP2 epitope sequence in Epstein-Barr virus-positive Hodgkin's disease.	HLA-A
9753343	10.1097/00007890-199809150-00013	1998	Low incidence of acute graft-versus-host disease, using unrelated HLA-A-, HLA-B-, and HLA-DR-compatible donors and conditioning, including anti-T-cell antibodies.	HLA-A
9780337	10.1056/NEJM199810223391701	1998	Effect of matching of class I HLA alleles on clinical outcome after transplantation of hematopoietic stem cells from an unrelated donor. Japan Marrow Donor Program.	HLA-A
8839770	10.1016/0198-8859(96)00031-6	1997	HLA-A11-mediated protection from NK cell-mediated lysis: role of HLA-A11-presented peptides.	HLA-A
9031102	10.3109/10428199609054824	1997	Unrelated donor bone marrow transplantation for hematological malignancies-current status.	HLA-A
9053477	10.1200/JCO.1997.15.2.557	1997	Unrelated donor bone marrow transplantation for children with acute leukemia.	HLA-A
9120290		1997	Conserved CTL epitopes within EBV latent membrane protein 2: a potential target for CTL-based tumor therapy.	HLA-A
9123502	10.1016/s0041-1345(96)00444-7	1997	A low incidence of grade II to IV acute GVHD, but high mortality from infection using HLA-A, -B, and -DR-identical unrelated donors and immunosuppression with ATG, cyclosporine, and methotrexate.	HLA-A
9156271	10.1038/sj.bmt.1700758	1997	Allogeneic peripheral blood stem cell transplant for myelodysplasia after chemotherapy for post-transplant lymphoma in a cardiac transplant recipient at 10 years.	HLA-A
9164184	10.1200/JCO.1997.15.5.1767	1997	Results of allogeneic bone marrow transplants for leukemia using donors other than HLA-identical siblings.	HLA-A
9169639	10.1038/sj.bmt.1700787	1997	Donor search or autografting in patients with acute leukaemia who lack an HLA-identical sibling? A matched-pair analysis. Acute Leukaemia Working Party of the European Cooperative Group for Blood and Marrow Transplantation (EBMT) and the International Marrow Unrelated Search and Transplant (IMUST) Study.	HLA-A
9240420	10.1006/bbrc.1997.6904	1997	Correlation between direct binding ability of synthetic T. gondii SAG1 peptides to HLA-A2 measured by a sensor for surface plasmon resonance and antigenicity of the peptides for T. gondii-infected cell-specific CTL.	HLA-A
9259400	10.1002/(sici)1097-0215(19970807)72:4&lt;614::aid-ijc11&gt;3.0.co;2-b	1997	Determination of HLA-A*02 antigen status in Hodgkin's disease and analysis of an HLA-A*02-restricted epitope of the Epstein-Barr virus LMP-2 protein.	HLA-A
9275365		1997	Recombinant human granulocyte colony-stimulating factor after allogeneic bone marrow transplantation.	HLA-A
9384487	10.1038/sj.bmt.1700967	1997	Successful treatment of severe cytomegalovirus retinitis with foscarnet and intraocular injection of ganciclovir in a myelosuppressed unrelated bone marrow transplant patient.	HLA-A
8547235	10.1111/j.1744-313x.1995.tb00243.x	1996	Rapid characterization of HLA class I alleles by gene mapping using ARMS PCR.	HLA-A
8666195		1996	[An analysis of the associational connections of immunogenetic blood markers with lymphogranulomatosis in Armenians].	HLA-A
8722340		1996	Transplantation of peripheral blood progenitor cells from unrelated donors.	HLA-A
8765034	10.1002/eji.1830260831	1996	Transporter (TAP)-independent processing of a multiple membrane-spanning protein, the Epstein-Barr virus latent membrane protein 2.	HLA-A
8790160	10.1046/j.1365-2141.1996.d01-1834.x	1996	Unrelated donor bone marrow transplantation for children with relapsed acute lymphoblastic leukaemia in second complete remission.	HLA-A
8813950	10.1136/jcp.49.7.545	1996	HLA antigen expression in enteropathy associated T cell lymphoma.	HLA-A
8816400		1996	Supramolecular complexes of MHC class I, MHC class II, CD20, and tetraspan molecules (CD53, CD81, and CD82) at the surface of a B cell line JY.	HLA-A
8820568	10.1016/0966-842X(96)81512-5	1996	The implications for childhood leukemia of infection with adenovirus.	HLA-A
7595202	10.1084/jem.182.5.1315	1995	Human CD8 transgene regulation of HLA recognition by murine T cells.	HLA-A
7601573	10.1002/ijc.2910620117	1995	Mechanisms of allele-selective down-regulation of HLA class I in Burkitt's lymphoma.	HLA-A
7620176		1995	The outcome of matched unrelated donor bone marrow transplantation in patients with hematologic malignancies using molecular typing for donor selection and graft-versus-host disease prophylaxis regimen of cyclosporine, methotrexate, and prednisone.	HLA-A
7744880	10.1074/jbc.270.20.12276	1995	The human leukocyte antigen A2 interferon-stimulated response element consensus sequence binds a nuclear factor required for constitutive expression.	HLA-A
7761977	10.1111/j.1399-0039.1995.tb02437.x	1995	The HLA-A,B,C genotype of the class I negative cell line Daudi reveals novel HLA-A and -B alleles.	HLA-A
7773222		1995	Allogeneic bone marrow transplantation for Hodgkin's and non-Hodgkin's lymphoma.	HLA-A
7995948		1995	Enhanced cytotoxicity of IFN-gamma-producing CD4+ cytotoxic T lymphocytes specific for T. gondii-infected human melanoma cells.	HLA-A
7504327	10.1111/j.1399-0039.1993.tb02162.x	1994	A human monoclonal antibody, produced following in vitro immunization, recognizing an epitope shared by HLA-A2 subtypes and HLA-A28.	HLA-A
7511684	10.1084/jem.179.4.1297	1994	T cell responses and virus evolution: loss of HLA A11-restricted CTL epitopes in Epstein-Barr virus isolates from highly A11-positive populations by selective mutation of anchor residues.	HLA-A
7512645		1994	Isolation of naturally processed peptides from a Toxoplasma gondii-infected human B lymphoma cell line that are recognized by cytotoxic T lymphocytes.	HLA-A
7515326	10.1002/1097-0142(19940615)73:12&lt;3059::aid-cncr2820731226&gt;3.0.co;2-q	1994	Epstein-Barr virus positivity in Hodgkin's disease does not correlate with an HLA A2-negative phenotype.	HLA-A
7909466	10.3109/10428199409059592	1994	Human major histocompatibility complex contains several leukemia susceptibility genes.	HLA-A
8052827		1994	[Immunoproliferative small intestinal disease (IPSID): an unusual form of gastrointestinal lymphoma].	HLA-A
8107207	10.1128/JVI.68.3.1442-1448.1994	1994	Down-regulation of HLA antigens by the adenovirus type 2 E3/19K protein in a T-lymphoma cell line.	HLA-A
8111046		1994	Recognition of minor histocompatibility antigens on lymphocytic and myeloid leukemic cells by cytotoxic T-cell clones.	HLA-A
8251898	10.3109/10428199309047888	1994	Treatment of CML with unrelated donor marrow transplant.	HLA-A
8284785	10.1111/j.1399-0039.1993.tb02178.x	1994	Modulation of cell surface antigens and regulation of phagocytic activity mediated by CD11b in the monocyte-like cell line U937 in response to lipopolysaccharide.	HLA-A
8302299	10.1016/0161-5890(94)90138-4	1994	Generation of HLA-B55 restricted T lymphocyte mediated cytotoxicity against autologous LCL.	HLA-A
1282031	10.1093/intimm/4.11.1283	1993	Immune escape by Epstein-Barr virus (EBV) carrying Burkitt's lymphoma: in vitro reconstitution of sensitivity to EBV-specific cytotoxic T cells.	HLA-A
8103717	10.1111/j.1365-2249.1993.tb08185.x	1993	Lysis of CD4+ lymphocytes by non-HLA-restricted cytotoxic T lymphocytes from HIV-infected individuals.	HLA-A
8214004		1993	Major histocompatibility complex class I and class II antigen expression in diffuse large cell and large cell immunoblastic lymphomas. Absence of a correlation between antigen expression and clinical outcome.	HLA-A
1321426	10.1073/pnas.89.13.5862	1992	Recognition of the Epstein-Barr virus-encoded nuclear antigens EBNA-4 and EBNA-6 by HLA-A11-restricted cytotoxic T lymphocytes: implications for down-regulation of HLA-A11 in Burkitt lymphoma.	HLA-A
1374446		1992	Role of endogenous peptides in murine allogenic cytotoxic T cell responses assessed using transfectants of the antigen-processing mutant 174xCEM.T2.	HLA-A
1729379		1992	Shared human melanoma antigens. Recognition by tumor-infiltrating lymphocytes in HLA-A2.1-transfected melanomas.	HLA-A
1790428		1992	Allogeneic bone marrow transplantation using unrelated donors: a pilot study of the Canadian Bone Marrow Transplant Group.	HLA-A
1792911	10.1111/j.1442-200x.1991.tb02580.x	1992	Immunological classification of childhood acute lymphoblastic leukemia.	HLA-A
1655115		1991	Cell phenotype dependent expression of MHC class I antigens in Burkitt's lymphoma cell lines.	HLA-A
1899854	10.1002/ijc.2910470412	1991	Aberrant expression of HLA class-I antigens in Burkitt lymphoma cells.	HLA-A
1909640	10.1002/eji.1830210909	1991	A quantitative assay of peptide-dependent class I assembly.	HLA-A
2041683		1991	[Prognostic factors in the development and course of acute lymphoblastic leukemia in children].	HLA-A
2066181	10.1002/ijc.2910470703	1991	Differential transcription inducibility by interferon of the HLA-A3 and HLA-B7 class-I genes.	HLA-A
2249952	10.1016/0198-8859(90)90071-v	1991	Effect of HLA incompatibility on graft-versus-host disease, relapse, and survival after marrow transplantation for patients with leukemia or lymphoma.	HLA-A
2251046		1991	[Histocompatibility antigens in children with acute lymphoblastic leukemia].	HLA-A
2253044		1991	[Familial occurrence of Hodgkin's disease].	HLA-A
2266272	10.1111/j.1744-313x.1990.tb00868.x	1991	Altered expression of HLA-A,B specificities on acute lymphoid and myeloid leukaemia blasts.	HLA-A
2395381		1990	Immunophenotypic and HLA studies in childhood acute lymphoblastic leukemia in Trinidad, West Indies.	HLA-A
2481537		1990	[International bone marrow donor exchange].	HLA-A
2472315		1989	[HLA and leukemia].	HLA-A
2535859		1989	IFN-mediated differential regulation of the expression of HLA-B7 and HLA-A3 class I genes.	HLA-A
2643045	10.1056/NEJM198901263200401	1989	Effect of HLA compatibility on engraftment of bone marrow transplants in patients with leukemia or lymphoma.	HLA-A
2744385		1989	[Class I and II HLA antigens in children with acute lymphoblastic leukemia].	HLA-A
2787418		1989	[Two cases of B-cell lymphoma occurring in a mother and her daughter at the same time].	HLA-A
2788584		1989	Study of HLA antigens in patients with Hodgkin's disease.	HLA-A
2804917	10.1002/1097-0142(19891201)64:11&lt;2259::aid-cncr2820641113&gt;3.0.co;2-0	1989	Possible disorder of B-cell-related surveillance and malignant lymphoma of the thyroid.	HLA-A
3199882		1989	HLA-A11 is associated with poor prognosis in childhood acute lymphoblastic leukemia (ALL).	HLA-A
3209056	10.1002/gepi.1370050609	1989	Significant association of acute lymphoblastic leukemia with HLA-Cw7.	HLA-A
3131426		1988	Isolation and nucleotide sequence of a cDNA clone encoding a novel HLA class I gene.	HLA-A
3257383		1988	Anti-Leu-3a antibody reactivity with Reed-Sternberg cells of Hodgkin's disease.	HLA-A
3037521	10.1073/pnas.84.13.4567	1987	Down-regulation of class I HLA antigens and of the Epstein-Barr virus-encoded latent membrane protein in Burkitt lymphoma lines.	HLA-A
3103712		1987	Mediastinal lymphoma of clear cell type is a tumor corresponding to terminal steps of B cell differentiation.	HLA-A
3298077	10.1002/ijc.2910400107	1987	Defective expression of MHC class I antigens is frequent in B-cell lymphomas of high-grade malignancy.	HLA-A
3491784		1987	The primary mediastinal clear cell lymphoma of B-cell type has variable defects in MHC antigen expression.	HLA-A
2423453	10.3109/08820138609042018	1986	Study on the association of HLA with malignant lymphoma.	HLA-A
2937619	10.1378/chest.89.4.545	1986	Pulmonary lymphoid neoplasms. Role of immunohistology in the study of cellular immunotypes and in differential diagnosis.	HLA-A
2999248		1986	Macrophage cytotoxicity: interleukin 1 as a mediator of tumor cytostasis.	HLA-A
3092030	10.1016/0161-5890(86)90115-x	1986	The synthesis and expression of HLA-A and -B antigens in Xenopus laevis oocytes.	HLA-A
2578520		1985	Delineation of three subsets of class I human T antigens (HTA) on Molt-4 cells: serologic and regulatory relationship to HLA class I antigens.	HLA-A
2580457	10.1016/0003-2697(85)90083-1	1985	Immunoblot specificity of monoclonal antibodies assayed against complex extracts.	HLA-A
3872842	10.1007/BF00375380	1985	Refinement of HLA gene mapping with induced B-cell line mutants.	HLA-A
3872893	10.1016/s0190-9622(85)70075-8	1985	Human leukocyte antigens in cutaneous T cell lymphoma.	HLA-A
3930277		1985	HLA class-I and class-II antigen expression by human leukemic K562 cells and by Burkitt-K562 hybrids: modulation by differentiation inducers and interferon.	HLA-A
6096637	10.1016/0145-2126(84)90050-x	1985	Differential methylation of class I histocompatibility antigen genes in T-cell lines derived from two different types of T-cell malignancies.	HLA-A
6390442	10.1073/pnas.81.23.7549	1985	Recognition of HLA-A2 and -B7 antigens by cloned cytotoxic T lymphocytes after gene transfer into human and monkey, but not mouse, cells.	HLA-A
6396193	10.1002/hon.2900020409	1985	Serum beta 2-microglobulin in lymphoproliferative and myeloproliferative diseases.	HLA-A
6197461		1984	Cytotoxic T lymphocyte recognition of HLA-A/B antigens introduced into EL4 cells by cell-liposome fusion.	HLA-A
6361126		1984	Introduction of HLA-A/B antigens into lymphoid cell membranes by cell-liposome fusion.	HLA-A
6693298	10.1016/0198-8859(84)90003-x	1984	Characterization of a murine monoclonal antibody specific for human early lymphohemopoietic cells.	HLA-A
6133389	10.1007/BF02890379	1983	Human dendritic reticulum cells of lymphoid follicles: their antigenic profile and their identification as multinucleated giant cells.	HLA-A
6185189		1983	[Effect of interferon on human cell lines which do not express class I transplantation antigens: K 562 and Daudi. Presence of a pseudo-messenger RNA of beta 2-microglobulin in Daudi cell line].	HLA-A
6186603	10.1007/BF00364752	1983	Presence of an abnormal beta 2-microglobulin mRNA in Daudi cells: induction by interferon.	HLA-A
6187075	10.1007/BF01543018	1983	HLA antigen expression at the single cell level on a K562 X B cell hybrid: an analysis with monoclonal antibodies using bacterial binding assays.	HLA-A
6303316	10.1042/bj2100079	1983	Human class I histocompatibility antigens (HLA-A,B,C). A small proportion only is phosphorylated.	HLA-A
6311905		1983	Cell surface antigen expression in newborn cord blood lymphocytes infected with HTLV.	HLA-A
6346116		1983	Differentiation of human myeloid leukemia cell lines induced by tumor-promoting phorbol ester (TPA). I. Changes of the morphology, cytochemistry and the surface differentiation antigens analyzed with monoclonal antibodies.	HLA-A
6578173	10.1136/gut.24.10.925	1983	HLA antigens in coeliac disease associated with malignancy.	HLA-A
6601679	10.1111/1523-1747.ep12553615	1983	Association of HLA-DR5 with mycosis fungoides.	HLA-A
6760459	10.1111/j.1399-0039.1982.tb02252.x	1983	HLA typing in non-Hodgkin's lymphomas. Comparative study in Caucasoids, Mexican-Americans and Negroids.	HLA-A
6888549	10.1038/305058a0	1983	Cell lines producing human T-cell lymphoma virus show altered HLA expression.	HLA-A
6888550	10.1038/305060a0	1983	Homology of human T-cell leukaemia virus envelope gene with class I HLA gene.	HLA-A
6960462		1983	[Detection of HLA-A, B and C antigens on various normal and pathologic cells using the monoclonal antibody W6/32].	HLA-A
7141899	10.1016/0198-8859(82)90055-6	1983	HLA antigens in East African Black patients with Burkitt's lymphoma or nasopharyngeal carcinoma and in controls: a pilot study.	HLA-A
6181407		1982	Lack of expression of HLA-ABC antigens in choriocarcinoma and other human tumor cell lines.	HLA-A
6289490	10.1111/j.1399-0039.1982.tb00328.x	1982	A new Epstein-Barr virus negative Burkitt's lymphoma derived cell-line. I. Analysis of cell surface markers and abnormal expression of HLA antigens.	HLA-A
6951167	10.1073/pnas.79.4.1190	1982	Introduction of a human X-6 translocation chromosome into a mouse teratocarcinoma: investigation of control of HLA-A, B, C expression.	HLA-A
7031655	10.1073/pnas.78.10.6485	1982	Monoclonal antibody against a Burkitt lymphoma-associated antigen.	HLA-A
6781554		1981	Altered expression of histocompatibility antigens on B large cell lymphomas.	HLA-A
7000762		1981	Biosynthesis of HLA-A and HLA-B antigens in vivo.	HLA-A
7263312	10.1016/0198-8859(80)90015-4	1981	Study of the HLA system in Burkitt's lymphoma.	HLA-A
7466791	10.1111/j.1399-0039.1980.tb00314.x	1981	B15 heterogeneity in East African Blacks.	HLA-A
6157763		1980	Expression of HLA-A, -B, and -C and beta 2-microglobulin antigens in human choriocarcinoma cell lines.	HLA-A
6447164	10.1172/JCI109828	1980	Autologous mixed lymphocyte reaction in patients with Hodgkin's disease. Evidence for a T cell defect.	HLA-A
85554		1979	Internal synthesis of p23,30 by several lymphoid malignancies.	HLA-A
77551	10.1111/j.1365-3083.1978.tb00444.x	1978	Reactivity of a rabbit antiserum against highly purified HLA-DR antigens.	HLA-A
796392	10.1111/j.1744-313x.1976.tb00605.x	1977	Chemotherapy--one of the causes of transient loss of HLA antigens and lymphocyte polyreactivity in patients with blood diseases and malignancies.	HLA-A
